10) ont déclaré un défaut d'observance. -100% (10/10) avaient un antécédent de traitement par INI de première génération, contre 70% (26/37) des patients en succès, avec dans 100% des cas un antécédent d'échec sous ce traitement, p.49 ,
9%) étaient dyslipidémiques Parmi eux, 12 étaient sous traitement hypolipémiant Sur ces 12 patients, aucun n'a nécessité de majoration du traitement hypolipémiant après mise sous DTG. En revanche, 4 ont pu bénéficier de l'arrêt ou de l'allègement de ce traitement. Dans 1 cas il s'agissait d'un patient chez qui un traitement par ETV avait été arrêté Dans un cas, seule l'IP avait été modifiée (passage de DRV/r+EPV à TPV/r+ EPV+ DTG+ T20) Dans un cas, un traitement par Trizivir avait été remplacé par ABC, 3TC+DTG. Enfin, pp.22-48 ,
une stratégie avec IP à une stratégie sans IP. Dans 1 cas le patient n'avait pas d'IP initialement, dans 1 cas l'IP a été maintenu dans le traitement avec le DTG, dans deux cas l'IP a été modifiée ,
Human immunodeficiency virus and related retroviruses, West J Med. déc, vol.147, issue.6, pp.702-710, 1987. ,
Morphogenesis and morphology of HIV structure-function relations, Archives of Virology, vol.332, issue.1-2, pp.1-13, 1989. ,
DOI : 10.1007/BF01311033
Role of viral regulatory and accessory proteins in HIV-1 replication, Frontiers in Bioscience, vol.9, issue.1-3, pp.2388-413, 2004. ,
DOI : 10.2741/1403
infection à VIH, Rev Prat. Fevrier, vol.62, issue.2, pp.255-63, 2012. ,
Diversit?? g??n??tique des VIH et ses cons??quences, Pathologie Biologie, vol.57, issue.2, pp.142-150, 2009. ,
DOI : 10.1016/j.patbio.2008.04.004
A new human immunodeficiency virus derived from gorillas, Nature Medicine, vol.24, issue.8, pp.871-873, 2009. ,
DOI : 10.1038/nm.2016
New concepts in the immunopathogenesis of human immunodeficiency virus infection, N Engl J Med. 4 févr, vol.328, issue.5, pp.327-362, 1993. ,
Targeting early infection to prevent HIV-1 mucosal transmission, Nature, vol.183, issue.7286, pp.217-240, 2010. ,
DOI : 10.1038/nature08757
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease, Nature, vol.362, issue.6418, pp.355-363, 1993. ,
DOI : 10.1038/362355a0
Human Immunodeficieny Virus Pathogenesis and Prospects for Immune Control in Patients with Established Infection, Clinical Infectious Diseases, vol.32, issue.12, pp.1756-68, 2001. ,
DOI : 10.1086/320759
Immunopathogenesis of acute AIDS virus infection, Current Opinion in Immunology, vol.18, issue.4, pp.399-405, 2006. ,
DOI : 10.1016/j.coi.2006.05.001
Evolution and plasticity of CTL responses against HIV, Current Opinion in Immunology, vol.8, issue.4, pp.546-53, 1996. ,
DOI : 10.1016/S0952-7915(96)80045-8
Immune activation and inflammation in HIV-1 infection: causes and consequences, The Journal of Pathology, vol.125, issue.2, pp.231-272, 2008. ,
DOI : 10.1002/path.2276
A long-term latent reservoir for HIV-1: discovery and clinical implications, Journal of Antimicrobial Chemotherapy, vol.54, issue.1, pp.6-9, 2004. ,
DOI : 10.1093/jac/dkh292
HIV immunopathogenesis and strategies for intervention, The Lancet Infectious Diseases, vol.8, issue.11, pp.675-84, 2008. ,
DOI : 10.1016/S1473-3099(08)70205-6
Infection by Human Immunodeficiency Virus ??? CD4 is Not Enough, New England Journal of Medicine, vol.335, issue.20, pp.1528-1558, 1996. ,
DOI : 10.1056/NEJM199611143352011
Single-pill combination regimens for treatment of HIV-1 infection, N Engl J Med. 17 juill, vol.371, issue.3, pp.248-59, 2014. ,
Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy, New England Journal of Medicine, vol.340, issue.21, pp.1614-1636, 1999. ,
DOI : 10.1056/NEJM199905273402102
A new classification for HIV-1, Nature, vol.391, issue.6664, p.240, 1998. ,
DOI : 10.1038/34571
Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis, European Journal of Clinical Microbiology & Infectious Diseases, vol.22, issue.14, pp.779-86, 2010. ,
DOI : 10.1007/s10096-010-0926-y
HLA-B*5701 testing to predict abacavir hypersensitivity, PLoS Currents, vol.2, p.1203, 2010. ,
DOI : 10.1371/currents.RRN1203
Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'expert, 2013. ,
Prise en charge médicales des patients vivant avec le VIH. Actualisation, 2013. ,
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors, Virus Research, vol.134, issue.1-2, pp.147-56, 2008. ,
DOI : 10.1016/j.virusres.2008.01.002
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies, J Antimicrob Chemother. juill, vol.70, issue.7, pp.2084-2093, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01486966
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability, Journal of the International AIDS Society, vol.16, issue.1, pp.1-14, 2013. ,
DOI : 10.7448/IAS.16.1.18567
Integrase inhibitors to treat HIV/Aids, Nature Reviews Drug Discovery, vol.17, issue.3, pp.236-284, 2005. ,
DOI : 10.1038/nrd1660
Resistance to Integrase Inhibitors, Viruses, vol.2, issue.7, pp.1347-66, 2010. ,
DOI : 10.3390/v2071347
Structures et rôles de l'intégrase dans le cycle viral, Virologie, vol.11, issue.35, pp.143-52, 2007. ,
Raltegravir: molecular basis of its mechanism of action, European Journal of Medical Research, vol.14, issue.Suppl 3, pp.5-16, 2009. ,
DOI : 10.1021/jm025553u
Integrase and integration: biochemical activities of HIV-1 integrase, Retrovirology, vol.5, issue.1, p.114, 2008. ,
DOI : 10.1186/1742-4690-5-114
Raltegravir, Drugs, vol.43, issue.5, pp.131-139, 2008. ,
DOI : 10.2165/00003495-200868010-00009
Integrase Strand Transfer Inhibitors in HIV Therapy, Infectious Diseases and Therapy, vol.10, issue.1, pp.83-93, 2013. ,
DOI : 10.1007/s40121-013-0020-8
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells, Science, vol.287, issue.5453, pp.646-50, 2000. ,
DOI : 10.1126/science.287.5453.646
Structural Determinants for HIV-1 Integrase Inhibition by ??-Diketo Acids, Journal of Biological Chemistry, vol.277, issue.15, pp.12596-603, 2002. ,
DOI : 10.1074/jbc.M110758200
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1???Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.1, pp.77-85, 1999. ,
DOI : 10.1097/QAI.0b013e31828ace69
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor???Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1, Annals of Internal Medicine, vol.161, issue.7, pp.461-71, 2014. ,
DOI : 10.7326/M14-1084
Ritonavirboosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet. 4 août, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01108186
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, The Lancet Infectious Diseases, vol.13, issue.7, pp.587-96, 2013. ,
DOI : 10.1016/S1473-3099(13)70093-8
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study, Lancet. 15 juin, vol.381, issue.9883, pp.2091-2100, 2013. ,
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials, The Lancet, vol.375, issue.9712, pp.396-407, 2010. ,
DOI : 10.1016/S0140-6736(09)62041-9
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study, AIDS, vol.24, issue.11, pp.1697-707, 2010. ,
DOI : 10.1097/QAD.0b013e32833a608a
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study), Scandinavian Journal of Infectious Diseases, vol.26, issue.1, pp.34-45, 2014. ,
DOI : 10.1016/S0140-6736(02)08706-8
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial, Journal of Antimicrobial Chemotherapy, vol.66, issue.9, pp.2099-106, 2011. ,
DOI : 10.1093/jac/dkr269
A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study, AIDS Research and Human Retroviruses, vol.28, issue.10, pp.1196-206, 2012. ,
DOI : 10.1089/aid.2011.0336
Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial, PLoS ONE, vol.28, issue.8, p.73639, 2013. ,
DOI : 10.1371/journal.pone.0073639.s002
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial, The Lancet Infectious Diseases, vol.11, issue.12, pp.907-922, 2011. ,
DOI : 10.1016/S1473-3099(11)70196-7
Barri??re g??n??tique ?? la r??sistance des antir??troviraux, M??decine et Maladies Infectieuses, vol.40, issue.1, pp.1-10, 2010. ,
DOI : 10.1016/S0399-077X(10)70001-9
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, New England Journal of Medicine, vol.359, issue.4, pp.355-65, 2008. ,
DOI : 10.1056/NEJMoa0708978
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens, Journal of Antimicrobial Chemotherapy, vol.65, issue.6, pp.1262-1271, 2010. ,
DOI : 10.1093/jac/dkq099
URL : https://hal.archives-ouvertes.fr/hal-00594696
Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences, Current Opinion in Virology, vol.8, pp.98-103, 2014. ,
DOI : 10.1016/j.coviro.2014.07.006
Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3187-94, 2011. ,
DOI : 10.1128/AAC.00071-11
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1351-1359, 2008. ,
DOI : 10.1128/AAC.01228-07
Test génotypique de résistance aux inhibiteurs de l'intégrase ? Rapport d'évaluation, 2010. ,
The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions, PLoS ONE, vol.5, issue.4, p.10311, 2010. ,
DOI : 10.1371/journal.pone.0010311.s001
URL : https://hal.archives-ouvertes.fr/hal-00522695
Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics, Journal of Medicinal Chemistry, vol.49, issue.5, pp.1506-1514, 2006. ,
DOI : 10.1021/jm0600139
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.1, pp.96-100, 1999. ,
DOI : 10.1097/QAI.0b013e318289545c
Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, pp.2429-2467, 2012. ,
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.4, pp.494-501, 1999. ,
DOI : 10.1097/QAI.0b013e318298469c
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial, The Lancet Infectious Diseases, vol.14, issue.7, pp.581-590, 2014. ,
DOI : 10.1016/S1473-3099(14)70782-0
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial, The Lancet Infectious Diseases, vol.14, issue.7, pp.590-599, 2014. ,
DOI : 10.1016/S1473-3099(14)70796-0
Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1???Infected Subjects: 48 Weeks Data, HIV Clinical Trials, vol.17, issue.5, pp.51-57, 2014. ,
DOI : 10.1016/S0140-6736(12)60917-9
Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.1, pp.32-40, 1999. ,
DOI : 10.1097/QAI.0b013e3182645648
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings, HIVAIDS Auckl NZ, vol.4, pp.5-15, 2012. ,
Pharmacology of HIV integrase inhibitors, Current Opinion in HIV and AIDS, vol.7, issue.5, pp.390-400, 2012. ,
DOI : 10.1097/COH.0b013e328356e91c
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.60, issue.6, pp.1195-205, 2007. ,
DOI : 10.1093/jac/dkm364
Induction Effects of Ritonavir: Implications for Drug Interactions, Annals of Pharmacotherapy, vol.19, issue.3, pp.1048-59, 2008. ,
DOI : 10.1097/FTD.Ob013e318030defO
Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors, Infectious Diseases and Therapy, vol.22, issue.1, pp.111-133, 2013. ,
DOI : 10.1007/s40121-013-0013-7
Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.379, issue.10, pp.1107-1123, 2013. ,
DOI : 10.1002/phar.1237
Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.55, issue.3, pp.323-332, 1999. ,
DOI : 10.1097/QAI.0b013e3181eb376b
Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection, Drugs, vol.36, issue.3, pp.687-97, 2014. ,
DOI : 10.1007/s40265-014-0206-8
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors, Journal of Virology, vol.82, issue.21, pp.10366-74, 2008. ,
DOI : 10.1128/JVI.00470-08
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.2873-2881, 2012. ,
DOI : 10.1128/AAC.06170-11
Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Na??ve Patients, HIV Clinical Trials, vol.19, issue.4, pp.218-248, 2014. ,
DOI : 10.1093/infdis/jis750
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients, Antiviral Therapy, vol.20, issue.3, 2014. ,
DOI : 10.3851/IMP2885
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir, Clinical Pharmacokinetics, vol.37, issue.9, pp.981-94, 2013. ,
DOI : 10.1007/s40262-013-0093-2
Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572), Molecular Pharmacology, vol.80, issue.4, pp.565-72, 2011. ,
DOI : 10.1124/mol.111.073189
Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes, Antimicrobial Agents and Chemotherapy, vol.55, issue.10, pp.4552-4561, 2011. ,
DOI : 10.1128/AAC.00157-11
Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics, PLoS ONE, vol.49, issue.10, p.77448, 2013. ,
DOI : 10.1371/journal.pone.0077448.s002
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial, The Lancet Infectious Diseases, vol.12, issue.2, pp.111-119, 2012. ,
DOI : 10.1016/S1473-3099(11)70290-0
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial, The Lancet Infectious Diseases, vol.13, issue.11, pp.927-962, 2013. ,
DOI : 10.1016/S1473-3099(13)70257-3
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, The Lancet, vol.383, issue.9936, pp.2222-2253, 2014. ,
DOI : 10.1016/S0140-6736(14)60084-2
Dolutegravir plus Abacavir???Lamivudine for the Treatment of HIV-1 Infection, New England Journal of Medicine, vol.369, issue.19, pp.1807-1825, 2013. ,
DOI : 10.1056/NEJMoa1215541
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, The Lancet, vol.382, issue.9893, pp.700-708, 2013. ,
DOI : 10.1016/S0140-6736(13)61221-0
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study, Journal of Infectious Diseases, vol.207, issue.5, pp.740-748, 2013. ,
DOI : 10.1093/infdis/jis750
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study, Journal of Infectious Diseases, vol.210, issue.3, pp.354-62, 2014. ,
DOI : 10.1093/infdis/jiu051
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study, Antivir Ther. 16 oct, 2014. ,
Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir, Antimicrobial Agents and Chemotherapy, vol.56, issue.3, pp.1627-1636, 2012. ,
DOI : 10.1128/AAC.05739-11
Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.1, pp.254-262, 2010. ,
DOI : 10.1128/AAC.00842-09
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment, European Journal of Clinical Pharmacology, vol.51, issue.2, pp.29-35, 2014. ,
DOI : 10.1007/s00228-013-1590-9
Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.1, pp.21-28, 1999. ,
DOI : 10.1097/QAI.0b013e318276cda9
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat, Kidney International, vol.86, issue.2, pp.350-357, 2014. ,
DOI : 10.1038/ki.2014.66
Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults, Drugs, vol.21, issue.1, pp.1241-52, 2014. ,
DOI : 10.1007/s40265-014-0256-y
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects, British Journal of Clinical Pharmacology, vol.39, issue.2 Suppl. 1, pp.990-996, 2013. ,
DOI : 10.1111/j.1365-2125.2012.04440.x
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, pp.813-834, 2011. ,
DOI : 10.1128/AAC.01209-10
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound, Journal of the International AIDS Society, vol.17, issue.4(Suppl 3), 2014. ,
DOI : 10.7448/IAS.17.4.19518
Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses, pp.3377-85, 2014. ,
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir, Journal of Virology, vol.86, issue.5, pp.2696-705, 2012. ,
DOI : 10.1128/JVI.06591-11
Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir, Journal of Infectious Diseases, vol.204, issue.11, pp.1811-1816, 2011. ,
DOI : 10.1093/infdis/jir636
The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.3, pp.297-301, 1999. ,
DOI : 10.1097/QAI.0b013e31826bfd02
Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 ,
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor- Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) ,